Cassava Sciences IncNASDAQ:SAVA
- LAST PRICE28.5100
- TODAY'S CHANGE (%)0.1200 (0.4227%)
- Bid / Lots28.1100/ 2
- Ask / Lots28.4000/ 7
- Open / Previous Close28.2000 / 28.3900
- Day Range
- 52 Week Range
- Volume2,615,436
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Aug 8, 2024
DJ Cassava Sciences Price Target Maintained With a $107.00/Share by Rodman & Renshaw, from 2:37PM ET on Thursday Aug 08, 2024 by Dow Jones
2:37PM ET on Thursday Aug 08, 2024 by Dow Jones*DJ Cassava Sciences 2Q EPS 13c >SAVA, from 8:00AM ET on Thursday Aug 08, 2024 by Dow Jones
8:00AM ET on Thursday Aug 08, 2024 by Dow JonesCassava Sciences Reports Q2 2024 Financial Results and Operational Updates, from 8:00AM ET on Thursday Aug 08, 2024 by Dow Jones
8:00AM ET on Thursday Aug 08, 2024 by Dow Jones
Aug 5, 2024
DJ Francisco Partners, Robertson Stephens Founder Sandy Robertson Dies, from 10:11AM ET on Monday Aug 05, 2024 by Dow Jones
10:11AM ET on Monday Aug 05, 2024 by Dow JonesCassava Sciences Mourns the Death of Board Member Sanford "Sandy" Robertson, from 9:01AM ET on Monday Aug 05, 2024 by Dow Jones
9:01AM ET on Monday Aug 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cassava Sciences Inc | 1.4B | -70.3x | --- |
Longboard Pharmaceuticals Inc | 1.3B | -16.0x | --- |
Spyre Therapeutics Inc | 1.3B | -1.7x | --- |
Disc Medicine Inc | 1.4B | -13.1x | --- |
ARS Pharmaceuticals Inc | 1.3B | -28.6x | --- |
Centessa Pharmaceuticals PLC | 1.4B | -8.0x | --- |
Company Information
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
Contact Information
- Headquarters
- 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
- Phone
- 512-501-2444
- Fax
- 512-614-0414
Executives
- Executive Chairman of the Board
- Richard Barry
- Chief Financial Officer
- Eric Schoen
- Senior Vice President, General Counsel
- R. Christopher Cook
- Chief Medical Officer
- James Kupiec
- Lead Independent Director
- Sanford Robertson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.64 |
EPS | $-0.41 |
Book Value | $3.25 |
P/E Ratio | -70.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
